Navigation Links
Long-term ICS use reduces pleural effusion in patients with CAP
Date:5/23/2012

ATS 2012, SAN FRANCISCO Prior treatment with inhaled corticosteroids in patients with respiratory disorders who develop community acquired pneumonia (CAP) is associated with a lower incidence and severity of parapneumonic effusion, according to a new study from researchers in Spain.

A parapneumonic effusion is a type of pleural effusion (excess fluid that accumulates between the two pleural layers, the fluid-filled space that surrounds the lungs) that arises as a result of a pneumonia, lung abscess, or bronchiectasis.

"Long-term treatment with inhaled corticosteroids is associated with an elevated risk of CAP in patients with COPD, while at the same time, use of inhaled corticosteroids is also associated with less CAP severity and a lower risk of pneumonia-related mortality," said Jacobo Sellares, MD, PhD, associate faculty member at Hospital Clnic The August Pi I Sunyer Biomedical Research Institute (IDIBAPS) in Barcelona, Spain. "In our study, prior treatment with inhaled corticosteroids in patients who developed CAP was associated with a lower incidence and less severity of parapneumonic effusion, regardless of the patient's baseline chronic respiratory condition."

The results will be presented at the ATS 2012 International Conference in San Francisco.

The single center study enrolled 3,602 consecutive patients with a diagnosis of CAP. Of these, 659 (18%) had respiratory disorders treated with inhaled corticosteroids before CAP was diagnosed. Respiratory disorders included COPD (56%), asthma (13%), bronchiectasis (6%), and other disorders (25%).

Patients with prior treatment with inhaled corticosteroids, compared with those without, had a significantly lower incidence of parapneumonic effusion (5% vs. 12%). This association remained significant after adjustment for age, sex, comorbidities, and CAP severity. Prior corticosteroid treatment was associated with a higher incidence of simple parapneumonic effusion and a lower incidence of empyema compared with no prior corticosteroid treatment.

Baseline pulmonary disorder did not affect the relationship between corticosteroid treatment and parapneumonic effusion.

"Pleural infection is common in patients with CAP and is associated with an increased mortality risk," said Dr. Sellares. "Our results show that previous treatment of respiratory disorders with inhaled corticosteroids may reduce the risk of developing this dangerous complication."

The potential preventive role of inhaled corticosteroids in preventing parapneumonic effusion in patients with high risk of CAP must be clarified in future randomized studies, according to Dr. Sellares.


'/>"/>

Contact: Nathaniel Dunford
ndunford@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. More Research Points to Long-Term Ills With Bone Drugs
2. Study says children exposed to tobacco smoke face long-term respiratory problems
3. Many Primary Care Docs Dont Know Long-Term Effects of Chemo: Survey
4. Optimal care of bariatric surgery patients vital for long-term health and well-being
5. Supporting LGB children may influence their long-term health, BU study finds
6. Long-term neuropsychological impairment is common in acute lung injury survivors
7. Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC
8. Long-Term Estrogen Therapy Does Up Breast Cancer Risk: Study
9. U.S. Underestimates Long-Term Costs of Obesity, Experts Say
10. Groundbreaking, long-term study of head injuries among athletes kicks off with NCAA grant
11. HIV/AIDS vaccine shows long-term protection against multiple exposures in non-human primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... ... IT operations analytics and application performance monitoring (APM) solutions, has expanded its ... services providers. , According to Peter Ohrenberger, sales director at Nastel, “We’ve ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... platform, in which their iMedSecure™ comes included with each system installation. RMT’s ... images to remote participants for real-time collaboration and immediate decision-making requirements. While ...
(Date:7/20/2017)... ... July 20, 2017 , ... Vixiar ... non-invasive devices and systems for monitoring cardiopulmonary diseases, announced today that it has ... to complete regulatory submissions and fund final engineering and initial production of the ...
(Date:7/20/2017)... , ... July 20, 2017 , ... The Dermatology Clinic ... Dr. Dunbar received his BS in Biology from LSU, graduating summa cum laude. He ... Class President. After his residency in St. Louis, Dr. Dunbar moved to New York ...
(Date:7/20/2017)... CA (PRWEB) , ... July 20, 2017 , ... ... A Guide to the Business Architecture Body of Knowledge (BIZBOK® Guide )v 6.0 ... members who contributed to this effort through Guild collaborative teams. , Non-members may ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... , July 14, 2017 Endo International plc (NASDAQ: ... Tuesday, August 8, 2017.  Members of its senior management team will ... open at 8:30 a.m. ET. The dial-in number ... 497-0462, International (678) 509-7598, and the passcode is 45397076. Please dial ... A replay of the call will ...
(Date:7/12/2017)... is a revolutionary new product that relieves painful carpal tunnel syndrome ... affects more than 8 million people a year. Women suffer from ... methods of treating CTS are painful surgery, the use of NSAIDs ... ... a clear patch worn on the palm of the hand. It ...
(Date:7/11/2017)... , July 11, 2017  Sysmex America, Inc., ... diagnostic testing equipment as well as middleware information ... way to make quality assurance easier and more ... is well known for the innovation that it ... Monitor elevates quality assurance processes to a new ...
Breaking Medicine Technology: